New Orleans

Map Unavailable

Date(s) - March 20,2020 - March 22,2020
8:00 am - 1:00 pm

Loews New Orleans


HOTEL INFO: please call us to assist with room reservation

Loews New Orleans

group rate $239 per night single or double occupancy. Extra adult in room $30 per night

March 20, 2020

James Lewis, Pharm.D., FIDSA
University of Texas at San Antonio

Dr. James Lewis received his BPharm and Pharm.D. degrees from Washington State University and completed his PGY-2 infectious diseases residency at the University of Texas Health Sciences Center in San Antonio. Dr. Lewis currently serves as the infectious diseases pharmacy specialist and co-director of the antibiotic stewardship program at University Health System in San Antonio where is also an adjunct associate professor in the division of infectious diseases at the UT health sciences center. Dr. Lewis’ has published many abstracts at international meetings as well as peer reviewed papers in the areas of antifungal and antibacterial resistance as well as antibiotic stewardship. In addition he is a member of the editorial board of Clinical Microbiology Reviews and serves a serves as a reviewer for several other journals. In 2011 he was named a fellow of the infectious diseases society of America.



ACPE # 0043-9999-20-004-L01-P

1.  Describe the strengths and weaknesses of three widely used classes of systemic antifungal agents.
2.  List the most common pathogens in invasive fungal infections and their usual antifungal susceptibility profiles.
3.  Identify areas where further research is needed in the treatment of invasive fungal infections.

Saturday March 21, 2020

Dr. Reginal Harris, Pharm D, JD

Infosource Communications

Reginal Harris is the founder and president of Infosource Communications, a pharmacy consulting and professional speaking company, which offers continuous quality improvement programs, resource management consulting, mock Joint Commission accreditation surveys, and leadership mentoring and other clinical services. He has served on the college of pharmacy faculty for Texas A&M University Health Sciences Center and the University of Colorado Health Sciences Center. He is the author of Patient’s FIRST: A Case Study on How the Collaborative Approach to Patient Care Has Improved Overall Safety and Treatment Outcomes.


ACPE# 0043-9999-20-005-L01-P


1.  Outline the five MTM Core Elements and Centers for Medicare and Medicaid Services (CMS) Standardized Format necessary to provide Comprehensive and Targeted Medication Reviews.

2.  Create a Pharmacy Technician step-by-step process that schedules MTM services, completes outreach to patients or prescribers, and documents interventions on behalf of pharmacists; thereby reserving pharmacists’ time for counseling and clinical work.

3.  Discuss the importance of documentation, interventions, referral, and follow-up as they relate to identifying medication related problems, creating a medication action plan, and issuing  patient medication list.

4.  Incorporate CMS changes that enhance providing MTM services specifically (a) 2019 Donut Hole (coverage gap), (b) Medicare Advantage Open Enrollment Period (MA-OEP), and (c) 2020 Medicare Part D coverage changes.

5.  Obtain reimbursement and maximize revenue from CMS by completing comprehensive medication reviews and targeted interventions.

6.  Reinforce understanding of key MTM concepts and using CMS standardized format by completing a patient case study activity.

Sunday March 22, 2020

Dr. Reginal Harris, Pharm D, JD


ACPE# 0043-9999-20-006-L08-P


  1.  Define common terms relating to pathology of opioid misuse and addiction and what steps pharmacists can take when dispensing and counseling at-risk patients taking a controlled substance.
  2.  Describe how a state’s Prescription Drug Monitoring Program assists pharmacists when determining the validity, use, misuse, and abuse of controlled substances.
  3.  Describe how recent changes in the Controlled Substances Act help pharmacists identify “red flags” when receiving and evaluating controlled substance prescriptions.
  4.  Define the concept of Risk Evaluation & Mitigation Strategy (REMS) as an evidence-based approach of assessing patients with chronic pain who are initiated on opioid or other pain medications and how to calculate the morphine milligram equivalents.
  5. Apply standardized scales and tools to document pain characteristics and to guide medication management decisions by comparing/contrasting “strengths v. weaknesses” and “specificity v. sensitivity” of the scales and tools.
  6.  Explain the FDA evaluation blueprint as a tool to identify patients showing signs of addiction, abuse, misuse, or overuse of pain medications.
  7. Apply the REMS and/or FDA approach to develop a comprehensive, customized treatment plan for a patient initiated on an opioid analgesic or other pain medications.
  8. Document treatment recommendations using the S.O.A.P. format to reinforce patient-clinician responsibilities.


Bookings are closed for this event.

Don't have a Paypal account? You do not need a Paypal Account to pay with Paypal. Paypal allows you to pay online simply by entering your credit card and billing information.